Dr. Eric Leuthardt to Unveil Groundbreaking IpsiHand Study at ISC 2026
In an exciting announcement from Kandu, Inc., a pioneering healthcare technology firm, Dr. Eric Leuthardt will present groundbreaking findings on the IpsiHand® system at the International Stroke Conference (ISC) 2026 scheduled from February 4 to February 6, 2026, in New Orleans, Louisiana. This presentation is expected to fuel significant discussion in the medical community surrounding innovative strategies in post-stroke recovery.
Dr. Leuthardt, who serves as the Professor of Neurosurgery and Neurology at Washington University School of Medicine in St. Louis, will share the results of a randomized controlled trial titled "A randomized trial of an at-home brain computer interface therapy compared to standard exercise therapy for chronic upper extremity motor deficit after stroke." This important study, presented during the conference's closing plenary session on February 6, explores the clinical efficacy of Kandu’s IpsiHand® device. This FDA-cleared brain-computer interface is specifically designed to promote upper-extremity motor recovery in stroke survivors suffering from paralysis.
The trial represents a significant addition to the expanding body of research on the effectiveness of brain-computer interface technology in rehabilitating stroke patients. As Dr. Leuthardt notes, the results from this study will be crucial in illustrating how enhanced therapeutic approaches can potentially transform rehabilitation methods for chronic stroke patients. "The results being presented at ISC are from a randomized, post-market study that evaluates a brain-computer interface-enhanced approach compared to traditional home therapy for chronic stroke survivors engaged in upper extremity rehabilitation," he explained.
Furthermore, Kandu's engagement at ISC 2026 signifies their unwavering commitment to rigorously studying innovative solutions aimed at improving stroke recovery outcomes. According to Leo Petrossian, the CEO of Kandu, Inc., the company is enthusiastic about sharing vital trial data with the clinical and research community. “By sharing randomized trial data with the clinical and research community, we aim to support informed dialogue around the role of brain-computer interface technology in post-stroke care," Petrossian stated.
Apart from presenting the intriguing results of the trial, Kandu will also set up an exhibit at ISC 2026, providing an opportunity for clinicians, researchers, and health care professionals to engage and converse about the applications of brain-computer interface technology in stroke recovery.
Kandu, Inc. stands at the forefront of innovating integrated stroke recovery solutions, utilizing the powerful combination of FDA-cleared brain-computer interface technology and personalized care models to deliver comprehensive support for stroke survivors. Their flagship device, the IpsiHand®, empowers users to regain functional movement by harnessing neural intent and leveraging neuroplasticity. Kandu's offerings are curated to extend rehabilitation beyond clinical settings, ultimately striving to enhance the quality of life, mobility, and independence of stroke patients, while simultaneously generating sustainable value for patients, healthcare providers, and investors alike. For more information about these initiatives, the community is encouraged to visit Kandu's website at kandu.com.
In conclusion, the upcoming presentation at ISC 2026 by Dr. Eric Leuthardt has the potential to set a new benchmark in stroke recovery therapies, prompting further exploration and development of advanced rehabilitation methods that can positively impact thousands of lives.
Dr. Leuthardt, who serves as the Professor of Neurosurgery and Neurology at Washington University School of Medicine in St. Louis, will share the results of a randomized controlled trial titled "A randomized trial of an at-home brain computer interface therapy compared to standard exercise therapy for chronic upper extremity motor deficit after stroke." This important study, presented during the conference's closing plenary session on February 6, explores the clinical efficacy of Kandu’s IpsiHand® device. This FDA-cleared brain-computer interface is specifically designed to promote upper-extremity motor recovery in stroke survivors suffering from paralysis.
The trial represents a significant addition to the expanding body of research on the effectiveness of brain-computer interface technology in rehabilitating stroke patients. As Dr. Leuthardt notes, the results from this study will be crucial in illustrating how enhanced therapeutic approaches can potentially transform rehabilitation methods for chronic stroke patients. "The results being presented at ISC are from a randomized, post-market study that evaluates a brain-computer interface-enhanced approach compared to traditional home therapy for chronic stroke survivors engaged in upper extremity rehabilitation," he explained.
Furthermore, Kandu's engagement at ISC 2026 signifies their unwavering commitment to rigorously studying innovative solutions aimed at improving stroke recovery outcomes. According to Leo Petrossian, the CEO of Kandu, Inc., the company is enthusiastic about sharing vital trial data with the clinical and research community. “By sharing randomized trial data with the clinical and research community, we aim to support informed dialogue around the role of brain-computer interface technology in post-stroke care," Petrossian stated.
Apart from presenting the intriguing results of the trial, Kandu will also set up an exhibit at ISC 2026, providing an opportunity for clinicians, researchers, and health care professionals to engage and converse about the applications of brain-computer interface technology in stroke recovery.
Kandu, Inc. stands at the forefront of innovating integrated stroke recovery solutions, utilizing the powerful combination of FDA-cleared brain-computer interface technology and personalized care models to deliver comprehensive support for stroke survivors. Their flagship device, the IpsiHand®, empowers users to regain functional movement by harnessing neural intent and leveraging neuroplasticity. Kandu's offerings are curated to extend rehabilitation beyond clinical settings, ultimately striving to enhance the quality of life, mobility, and independence of stroke patients, while simultaneously generating sustainable value for patients, healthcare providers, and investors alike. For more information about these initiatives, the community is encouraged to visit Kandu's website at kandu.com.
In conclusion, the upcoming presentation at ISC 2026 by Dr. Eric Leuthardt has the potential to set a new benchmark in stroke recovery therapies, prompting further exploration and development of advanced rehabilitation methods that can positively impact thousands of lives.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.